Optimal post-treatment surveillance in cancer survivors: Is more really better?

ONCOLOGY (United States)

Volumn 29, Issue 4, 2015, Pages

  Shah, Megha ^a   Denlinger, Crystal S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVOR; COLONOSCOPY; COLORECTAL CANCER; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMAGING; MAMMOGRAPHY; META ANALYSIS (TOPIC); METASTASIS; POSITRON EMISSION TOMOGRAPHY; POST TREATMENT SURVIVAL; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSTATE CANCER; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES;

EID: 84927732328     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Hartigan-Blanche D, Forsythe LP, Alfano CM, et al. Provision and discussion of survivorship care plans among cancer survivors: results of a nationally representative survey of oncologists and primary care physicians. J Clin Oncol. 2014;32:1578-85.
2. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomark Prevent. 2013;23:561-7.
3. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy: a critical review and economic analysis. J Gen Int Med. 1997;12:318-31.
4. Virgo KS, Lerro CC, Klabunde CN, et al. Barriers to breast and colorectal cancer survivorship care. Perceptions of US primary care physicians and medical oncologists. J Clin Oncol. 2013;31:2322-36.
5. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009;251:175-84.
6. Ketchandji M, Kuo YF, Shahinian VB, et al. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009;57:24-30.
7. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252-71.
8. Hanks GE, Hanlon A, Schultheiss T, et al. Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol. 1994;152:1775-80.
9. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. Version 1.2015. Available from: http://www.nccn.org./professionals/physician_gls/pdf/prostate.pdf. Accessed March 11, 2015.
10. Skolarus TA, Wolf A, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64:225-49.
11. Obek C, Neulander E, Sadek S, et al. Is there a role for digital rectal examination in the follow-up of patients after radical prostatectomy? J Urol. 1999;162(3 Pt 1):762-64.
12. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005;173:797-802.
13. Wallace TJ, Torre T, Grob M, et al. Current approaches, challenges, and future directions for monitoring treatment response in prostate cancer. J Cancer. 2014;5:3-24.
14. Carroll P, Albertsen PC, Greene K, et al. PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 revision of 2009 best practice statement. Available from: https://www.auanet.org/common/pdf/education/clinicalguidance/ Prostate-Specific-Antigen.pdf. Accessed March 11, 2015.
15. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65:1034.
16. Zhou P, Chen MH, McLeod D, et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;28:6992-8.
17. Trock BJ, Han M, Freedland, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. AMA. 2008;299:2760-9.
18. Boorjian SA, Karnes RJ, Crispen PL, et al. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009;182: 2708-14.
19. Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-32.
20. Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60:205-10.
21. Nabhan M, Kim SP, Shah ND, et al. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcome: results from a population-based cohort. Mayo Clin Proc. 2012;87:540-7.
22. Freitas JE, Gilvydas R, Ferry JD, et al. The clinical utility of bone scintigraphy in prostate cancer followup. J Nucl Med. 1991;32:1387-90.
23. Teris MK, Klonecke AS, McDougall IR, et al. Utilization of bone scans in conjunction with prostatespecific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med. 1991;32:1713-7.
24. Skolarus TA, Wittmann D, Laurel N, et al. Recommendations for prostate cancer survivorshipcare: an update to the 2009 Michigan Cancer Consortium guidelines for the primary care
25. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
26. American Cancer Society. Colorectal cancer facts and figures 2014-2016. Available from: http://www.cancer.org/acs/content/documents/document/acspc-042280.pdf. Accessed March 11, 2015.
27. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872-7.
28. Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between 5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108:9-13.
29. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. Version 2.2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed March 11, 2015.
30. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: rectal cancer. Version 2.2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed March 20, 2015.
31. Desch CE, Benson AB, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512-9.
32. Anthony T, Simmang C, Hyman N, et al. Practice parameters for the surveillance and followup of patients with colon and rectal cancer. Dis Colon Rectum. 2004;47:807-17.
33. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high-risk groups (update from 2002). Gut.2010;59:666-89.
34. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-61.
35. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160-7.
36. Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer afteradjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002;136:261-9.
37. Pfister DG, Benson AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:2375-82.
38. Arnaud JP, Koehl C, Adloff M, et al. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980;23:141-4.
39. Tsikiris VL, Malireddy K, Green EA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy (COST) trial. J Clin Oncol. 2009;27:3671-6.
40. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783-99.
41. Carpentier MY, Vernon SW, Bartholomew LK, et al. Receipt of recommended surveillance amongcolorectal cancer survivors: a systematic review. J Cancer Surviv. 2013;7:464-83. Optimal Post-Treatment Surveillance in Cancer Survivors: Is More Published on Cancer Network (http://www.cancernetwork.com)
42. Pietra N, Sarli L, Costi R, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.
43. Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006;24:386-93
44. Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systemic review and meta-analysis of randomized trials. BMJ. 2002;324:813.
45. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2002;(1):CD002200
46. Ohlsson B, Breland U, Ekberg H, et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38:619-26.
47. Mäkelä JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg. 1995;130:1062-7.
48. Schoemaker D, Black R, Giles L, et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114:7-14.
49. Grossmann EM, Johnson FE, Virgo KS, et al. Follow-up of colorectal cancer patients after resection with curative intent—the GILDA trial. Surg Oncol. 2004;13:119-24.
50. Primrose JN, Perera R, Alastair G, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer. The FACS randomized clinical trial. JAMA. 2014;311:263-70.
51. Wille-Jorgensen P, Lauerberg S, Pahlman L, et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Dis. 2009;11:756-8.
52. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28:418-23.
53. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994;219:174-82.
54. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92.
55. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980-6.
56. van der Sangen MJ, Poortmans PM, Scheepers SW, et al. Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer. Eur JS Surg Oncol. 2013;39:892-8.
57. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 11, 2015.
58. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31;961-5.
59. Montgomery DA, Krupa A, Cooke TG. Follow-up in breast cancer: Does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007;97:1632-41.
60. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How? JAMA. 1999;282:1270-80.
61. Arasu VA, Joe BN, Lvoff NM, et al. Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology. 2012;264:371-7.
62. Lash TL, Fox MP, Silliman RA, et al. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J. 2006;12:2-6.
63. Schootman M, Jeffe DB, Lian M, et al. Surveillance mammogram and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111:489-96.
64. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394-1404.
65. Isasi CR, Moadel RM, Blaufox MD, et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12.
66. Kokko R, Holli K, Hakama M, et al. CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002;38:1189-93.
67. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicentre randomized controlled trial. JAMA. 1994;271:1587-92.
68. Del Turco RM, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1994;271:1593-7.
69. Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breastcancer: 10 year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.
70. Joseph E, Hyacinthe M, Lyman GH, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Onc. 1998;5:522-8.
71. Keating NL, Landrum MB, Guadagnoli E, et al. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25:1074-81.
72. Ramsey SD, Henry NL, Gralow JR, et al. Tumor marker usage and medical care costs amongolder early-stage breast cancer survivors. J Clin Oncol. 2014;33:149-55.
73. Grunfeld E, Hodgson DC, Del Giudice ME, et al. Population-based longitudinal study of follow-up care for breast cancer survivors. J Oncol Pract. 2010;6:174-81.
74. Margenthaler JA, Allam E, Chen L, et al. Surveillance of patients with breast cancer after curative-intent primary treatment: current practice patterns. J Oncol Pract. 2012;8:79-83.
75. American Board of Internal Medicine. Choosing Wisely Campaign Available from http://www.choosingwisely.org. Accessed March 11, 2015